Patents by Inventor Charles L. Sawyers

Charles L. Sawyers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED DIAZASPIROALKANES AS ANDROGEN RECEPTOR MODULATORS
    Publication number: 20240293383
    Abstract: Provided herein are hydantoin compounds useful for the prevention or treatment of hyperproliferative diseases or disorders.
    Type: Application
    Filed: October 2, 2023
    Publication date: September 5, 2024
    Inventors: Michael E. Jung, Charles L. Sawyers, Samedy Ouk, Chris Tran, John Wongvipat
  • DIARYLHYDANTOIN COMPOUNDS
    Publication number: 20240132452
    Abstract: The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
    Type: Application
    Filed: June 13, 2023
    Publication date: April 25, 2024
    Applicant: The Regents of the University of California
    Inventors: Charles L. Sawyers, Michael Jung, Charlie D. Chen, Samedy Ouk, Derek Welsbie, Chris Tran, John Wongvipat, Dongwon Yoo
  • Substituted diazaspiroalkanes as androgen receptor modulators
    Patent number: 11771687
    Abstract: Provided herein are hydantoin compounds useful for the prevention or treatment of hyperproliferative diseases or disorders.
    Type: Grant
    Filed: November 9, 2020
    Date of Patent: October 3, 2023
    Assignee: The Regents of the University of California
    Inventors: Michael E. Jung, Charles L. Sawyers, Samedy Ouk, Chris Tran, John Wongvipat
  • Modulators of resistant androgen receptor
    Patent number: 11739069
    Abstract: The present invention provides compounds useful as modulators, agonists or antagonists of androgen receptor (AR), compositions thereof, and methods of making and using the same.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: August 29, 2023
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Minna D. Balbas, Michael J. Evans, Charles L. Sawyers, Yang Shen, David Hosfield, Geoffrey L. Greene
  • DIARYLHYDANTOIN COMPOUNDS
    Publication number: 20230109968
    Abstract: The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
    Type: Application
    Filed: July 13, 2022
    Publication date: April 13, 2023
    Applicant: The Regents of the University of California
    Inventors: Charles L. SAWYERS, Michael JUNG, Charlie D. CHEN, Samedy OUK, Derek WELSBIE, Chris TRAN, John WONGVIPAT, Dongwon YOO
  • FREE PSA ANTIBODIES AS DIAGNOSTICS, PROGNOSTICS AND THERAPEUTICS FOR PROSTATE CANCER
    Publication number: 20230040245
    Abstract: The present invention provides methods of monitoring and measuring tumor-associated free PSA (“fPSA”) with antibody polypeptides as an indication of androgen receptor signaling. In a particular embodiment, the methods may be used to assess the efficacy of anti-androgen and/or general anti-cancer treatments. The present invention also provides various methods and compositions relating to antibodies that are specific for tumor-associated or intratumoral fPSA. For example, the present invention provides compositions, including pharmaceutical compositions, comprising anti-fPSA antibodies, or fragments or characterisitic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using anti-fPSA antibodies and/or compositions.
    Type: Application
    Filed: August 4, 2022
    Publication date: February 9, 2023
    Inventors: Charles L. Sawyers, David Ulmert, Jason Lewis, Michael J. Evans, Hans Lija
  • DIARYLHYDANTOIN COMPOUNDS
    Publication number: 20210238145
    Abstract: The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
    Type: Application
    Filed: November 3, 2020
    Publication date: August 5, 2021
    Applicant: The Regents of the University of California
    Inventors: Charles L. SAWYERS, Michael JUNG, Charlie D. CHEN, Samedy OUK, Derek WELSBIE, Chris TRAN, John WONGVIPAT, Dongwon YOO
  • GLUCOCORTICOID INHIBITORS FOR TREATMENT OF PROSTATE CANCER
    Publication number: 20210179660
    Abstract: The present invention encompasses the recognition that reproducible and detectable changes in the level and or activity of Glucorticoid Receptor (GR) are associated with incidence and/or risk of Castration Resistant Prostrate Cancer (CRPC) and/or doubly resistant prostrate cancer, especially in individuals having prostrate cancer and on antiandrogen therapy, and provides for the use of GR inhibitors to treat and/or reduce risk of CRPC and/or doubly resistant prostrate cancer. In some embodiments, GR inhibitors also have Androgen Receptors (AR) inhibitory activity and or administered in conjunction with AR Inhibitors. The present invention also provides technologies for identification and/or characterization of agents to treat and/or reduce risk of CRPC and/or doubly resistant prostrate cancer; in some embodiments such agents alter level and/or activity of a GR. In some embodiments, provided agents show effects on a GR's activity of regulating transcription of one or more target genes.
    Type: Application
    Filed: December 22, 2020
    Publication date: June 17, 2021
    Inventors: Vivek Arora, Charles L. Sawyers, Michael J. Evans, Darren R. Veach
  • ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES
    Publication number: 20210121450
    Abstract: Described herein, inter alia, are compounds useful for the prevention or treatment of hyperproliferative diseases or disorders.
    Type: Application
    Filed: November 9, 2020
    Publication date: April 29, 2021
    Inventors: Michael E. Jung, Charles L. Sawyers, Samedy Ouk, Chris Tran, John Wongvipat
  • Glucocorticoid inhibitors for treatment of prostate cancer
    Patent number: 10919929
    Abstract: The present invention encompasses the recognition that reproducible and detectable changes in the level and or activity of Glucocorticoid Receptor (GR) are associated with incidence and/or risk of Castration Resistant Prostate Cancer (CRPC) and/or doubly resistant prostate cancer, specifically in individuals having prostate cancer and on antiandrogen therapy, and provides for the use of GR inhibitors to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer. In some embodiments, GR inhibitors also have Androgen Receptor (AR) inhibitory activity or are administered in conjunction with AR inhibitors. The present invention also provides technologies for identification and/or characterization of agents to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer; in some embodiments such agents alter level and/or activity of a GR. In some embodiments, provided agents show effects on a GR's activity of regulating transcription of one or more target genes.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: February 16, 2021
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Vivek Arora, Charles L. Sawyers, Michael J. Evans, Darren R. Veach
  • Substituted diazaspiroalkanes as androgen receptor modulators
    Patent number: 10857139
    Abstract: Provided herein are compounds and pharmaceutical compositions including the compound having a formula: These compounds are androgen receptor modulators useful for the treatment of androgen receptor-associated conditions.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: December 8, 2020
    Assignee: The Regents of the University of California
    Inventors: Michael E. Jung, Charles L. Sawyers, Samedy Ouk, Chris Tran, John Wongvipat
  • MODULATORS OF RESISTANT ANDROGEN RECEPTOR
    Publication number: 20200172504
    Abstract: The present invention provides compounds useful as modulators, agonists or antagonists of androgen receptor (AR), compositions thereof, and methods of making and using the same.
    Type: Application
    Filed: October 21, 2019
    Publication date: June 4, 2020
    Inventors: Minna D. Balbas, Michael J. Evans, Charles L. Sawyers, Yang Shen, David Hosfield, Geoffrey L. Greene
  • DIARYLHYDANTOIN COMPOUNDS
    Publication number: 20200079741
    Abstract: The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
    Type: Application
    Filed: July 17, 2019
    Publication date: March 12, 2020
    Applicant: The Regents of the University of California
    Inventors: Charles L. SAWYERS, Michael JUNG, Charlie D. CHEN, Samedy OUK, Derek WELSBIE, Chris TRAN, John WONGVIPAT, Dongwon YOO
  • Modulators of resistant androgen receptor
    Patent number: 10450294
    Abstract: The present invention provides compounds useful as modulators, agonists or antagonists of androgen receptor (AR), compositions thereof, and methods of making and using the same.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: October 22, 2019
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Minna D. Balbas, Michael J. Evans, Charles L. Sawyers, Yang Shen, David Hosfield, Geoffrey L. Greene
  • DIARYLHYDANTOIN COMPOUNDS
    Publication number: 20190210974
    Abstract: The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
    Type: Application
    Filed: December 21, 2018
    Publication date: July 11, 2019
    Applicant: The Regents of the University of California
    Inventors: Charles L. SAWYERS, Michael JUNG, Charlie D. CHEN, Samedy OUK, Derek WELSBIE, Chris TRAN, John WONGVIPAT, Dongwon YOO
  • MUTATIONS IN THE BCR-ABL TYROSINE KINASE ASSOCIATED WITH RESISTANCE TO STI-571
    Publication number: 20190144946
    Abstract: The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS.
    Type: Application
    Filed: May 11, 2018
    Publication date: May 16, 2019
    Inventors: Charles L. Sawyers, Mercedes E. Gorre, Neil Pravin Shah, John Nicoll
  • Androgen receptor variants and methods for making and using
    Patent number: 10206911
    Abstract: The present invention encompasses the recognition that an F876L mutation of the androgen receptor (AR) gene confers resistance to the antiandrogens enzalutamide (MDV3100) and ARN-509 and is associated with incidence and/or risk of castration resistant prostate cancer (CRPC). The present invention also provides other AR polypeptide sequences associated with increased incidence and/or risk of CRPC. The present invention also provides screening methods for identification and/or characterization of novel AR polypeptide sequences associated with increased incidence and/or risk of CRPC via exposure to antiandrogens and for identification and/or characterization of agents to treat and/or reduce risk of CRPC by virtue of their effect on AR transcriptional activation.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: February 19, 2019
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Minna D. Balbas, Charles L. Sawyers, Philip Watson
  • ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES
    Publication number: 20180318276
    Abstract: Described herein, inter alia, are compounds useful for the prevention or treatment of hyperproliferative diseases or disorders.
    Type: Application
    Filed: May 2, 2018
    Publication date: November 8, 2018
    Inventors: Michael E. Jung, Charles L. Sawyers, Samedy Ouk, Chris Tran, John Wongvipat
  • Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571
    Patent number: 9994910
    Abstract: The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bu-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: June 12, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Charles L. Sawyers, Mercedes E. Gorre, Neil Pravin Shah, John Nicoll
  • Substituted diazaspiroalkanes as androgen receptor modulators
    Patent number: 9987261
    Abstract: Described herein, inter alia, are compounds useful for the prevention or treatment of hyperproliferative diseases or disorders.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: June 5, 2018
    Assignee: The Regents of the University of California
    Inventors: Michael E. Jung, Charles L. Sawyers, Samedy Ouk, Chris Tran, John Wongvipat